Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide

Details for Australian Patent Application No. 2005222909 (hide)

International Classifications

Event Publications

31 August 2006 PCT application entered the National Phase

PCT publication WO2005/089231 Priority application(s): WO2005/089231

19 October 2006 Assignment before Grant

The Immune Response Corporation; Hybridon, Inc. The application has been assigned to The Immune Response Corporation; Idera Pharmaceuticals, Inc.

11 March 2010 Application Accepted

Published as AU-B-2005222909

8 July 2010 Standard Patent Sealed

6 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.